Literature DB >> 11187907

mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method.

M G Rots1, J C Willey, G Jansen, C H Van Zantwijk, P Noordhuis, J P DeMuth, E Kuiper, A J Veerman, R Pieters, G J Peters.   

Abstract

Drug resistance of leukemic blasts is correlated to event-free survival and might be predicted by mRNA expression of drug resistance-related proteins. Methotrexate (MTX) is an important component in the treatment of childhood leukemia. Mechanisms of MTX resistance include (1) decreased transport via the reduced folate carrier (RFC), (2) altered levels of target enzymes, eg dihydrofolate reductase (DHFR) and thymidylate synthase (TS), (3) decreased ratio of folylpolyglutamate synthetase (FPGS)/folylpolyglutamate hydrolase (FPGH). We designed competitive templates for each of these genes to measure mRNA expression by quantitative RT-PCR and normalized the expression to that of beta-actin. T-lineage acute lymphoblastic leukemia (T-ALL), relatively MTX resistant compared to common/preB-ALL, displayed higher mRNA levels of DHFR and TS (three- and four-fold higher, respectively; P < 0.001), while FPGS expression was lower (three-fold, P = 0.006) compared to common/preB-ALL. The ratio of (DHFR x FPGH)/(RFC x FPGS) was more discriminating between T-ALL and c/preB-ALL (eight-fold higher; P < 0.001) than either target independently. Acute myeloid leukemia (AML) cells, considered MTX resistant, expressed two-fold lower levels of FPGS mRNA compared to c/preB-ALL (P = 0.04). The ratio of FPGH/FPGS was more discriminating between AML and c/preB-ALL (four-fold higher; P = 0.001) than either target independently. For the total group of 79 leukemic samples, mRNA expression of DHFR varied 549-fold and paralleled TS mRNA expression (r = 0.80; P < 0.001). Although variations in mRNA expression resembled variations in functional activity, no direct correlations were found for RFC (58-fold variation in mRNA expression), FPGS (95-fold) and FPGH (178-fold). In conclusion, differences in mRNA expression of MTX resistance parameters between leukemic subtypes as detected by competitive RT-PCR are in line with known differences in MTX resistance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11187907     DOI: 10.1038/sj.leu.2401943

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  17 in total

1.  Reproducible gene expression measurement among multiple laboratories obtained in a blinded study using standardized RT (StaRT)-PCR.

Authors:  E L Crawford; G J Peters; P Noordhuis; M G Rots; M Vondracek; R C Grafström; K Lieuallen; G Lennon; R J Zahorchak; M J Georgeson; A Wali; J F Lechner; P S Fan; M B Kahaleh; S A Khuder; K A Warner; D A Weaver; J C Willey
Journal:  Mol Diagn       Date:  2001-12

2.  Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines.

Authors:  Sara Nannizzi; Gareth J Veal; Elisa Giovannetti; Valentina Mey; Simona Ricciardi; Christopher J Ottley; Mario Del Tacca; Romano Danesi
Journal:  Cancer Chemother Pharmacol       Date:  2009-12-18       Impact factor: 3.333

3.  The association of aberrant folylpolyglutamate synthetase splicing with ex vivo methotrexate resistance and clinical outcome in childhood acute lymphoblastic leukemia.

Authors:  Anna Wojtuszkiewicz; Yehuda G Assaraf; Mirthe Hoekstra; Rocco Sciarrillo; Gerrit Jansen; Godefridus J Peters; Rob Pieters; Edwin Sonneveld; Gabriele Escherich; Gertjan J L Kaspers; Jacqueline Cloos
Journal:  Haematologica       Date:  2016-04-01       Impact factor: 9.941

4.  Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics.

Authors:  Leo Kager; Meyling Cheok; Wenjian Yang; Gianluigi Zaza; Qing Cheng; John C Panetta; Ching-Hon Pui; James R Downing; Mary V Relling; William E Evans
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

5.  Analysis of folylpoly-gamma-glutamate synthetase gene expression in human B-precursor ALL and T-lineage ALL cells.

Authors:  Guy J Leclerc; Gilles M Leclerc; Ting Ting Hsieh Kinser; Julio C Barredo
Journal:  BMC Cancer       Date:  2006-05-17       Impact factor: 4.430

6.  ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines.

Authors:  David A Weaver; Erin L Crawford; Kristy A Warner; Fadel Elkhairi; Sadik A Khuder; James C Willey
Journal:  Mol Cancer       Date:  2005-05-09       Impact factor: 27.401

7.  Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels.

Authors:  E Giovannetti; H H J Backus; D Wouters; C G Ferreira; V M M van Houten; R H Brakenhoff; M-F Poupon; A Azzarello; H M Pinedo; G J Peters
Journal:  Br J Cancer       Date:  2007-03-12       Impact factor: 7.640

8.  DHFR-mediated effects of methotrexate in medulloblastoma and osteosarcoma cells: the same outcome of treatment with different doses in sensitive cell lines.

Authors:  Jakub Neradil; Gabriela Pavlasova; Martin Sramek; Michal Kyr; Renata Veselska; Jaroslav Sterba
Journal:  Oncol Rep       Date:  2015-02-26       Impact factor: 3.906

9.  Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.

Authors:  A M Bergman; H M Pinedo; I Talianidis; G Veerman; W J P Loves; C L van der Wilt; G J Peters
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

10.  Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity.

Authors:  M de Bruin; T van Capel; K Van der Born; F A Kruyt; M Fukushima; K Hoekman; H M Pinedo; G J Peters
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.